Recent Price Movement and Market Context
On 26 Nov 2025, Vivo Bio Tech . recorded its lowest price in the past year at Rs.29.21, following a sequence of declines that have resulted in a cumulative return of -13.69% over the last ten days. This underperformance is notable against the Pharmaceuticals & Biotechnology sector, where the stock lagged by approximately 1.2% today. The broader market, represented by the Sensex, displayed resilience, closing at 85,070.93 points, up 0.57% and nearing its 52-week high of 85,801.70.
While the Sensex and mid-cap indices showed bullish momentum, Vivo Bio Tech . remained below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning indicates a persistent weakness in the stock’s price trend relative to market benchmarks.
Financial Performance and Growth Trends
Over the past year, Vivo Bio Tech . has delivered a total return of -25.42%, a stark contrast to the Sensex’s 6.34% gain during the same period. The company’s long-term sales growth has been subdued, with a compound annual growth rate (CAGR) of -0.84% in net sales over the last five years. This negative growth trajectory has contributed to the stock’s diminished appeal in the market.
Profitability metrics further illustrate the company’s challenges. The average return on equity (ROE) stands at 6.60%, indicating modest returns generated on shareholders’ funds. Additionally, the company’s ability to cover interest expenses is limited, with an average EBIT to interest ratio of 1.84, suggesting constrained financial flexibility.
Our latest monthly pick, this Large Cap from Aluminium & Aluminium Products, is outperforming the market! See the analysis that helped our Investment Committee select this winner.
- - Market-beating performance
- - Committee-backed winner
- - Aluminium & Aluminium Products standout
Recent Half-Year Results and Operational Metrics
The company’s latest half-year results reveal a subdued profit after tax (PAT) of Rs.2.21 crores, reflecting a decline of 59.07% compared to the previous corresponding period. Return on capital employed (ROCE) for the half-year is reported at 7.95%, one of the lowest levels recorded, signalling limited efficiency in generating returns from capital investments.
Further, the debtors turnover ratio stands at 3.54 times, indicating slower collection cycles relative to industry norms. These factors collectively highlight ongoing pressures on the company’s operational performance and cash flow management.
Valuation and Comparative Analysis
Despite the challenges, Vivo Bio Tech . exhibits a relatively attractive valuation profile. The enterprise value to capital employed ratio is approximately 0.8, suggesting the stock is trading at a discount compared to its peers’ historical averages. This valuation metric may reflect market caution given the company’s recent financial trends.
However, the stock’s profitability has contracted significantly, with profits falling by 45.2% over the past year. This decline in earnings has contributed to the stock’s downward trajectory and its current position near the 52-week low.
Considering Vivo Bio Tech .? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Shareholding and Market Position
The majority of Vivo Bio Tech .’s shares are held by non-institutional investors, which may influence the stock’s liquidity and trading patterns. The company operates within the Pharmaceuticals & Biotechnology sector, a space that has seen varied performance across different market capitalisation segments.
Over the last three years, Vivo Bio Tech . has consistently underperformed the BSE500 index, reflecting persistent challenges in maintaining competitive growth and profitability relative to broader market peers.
Summary of Key Concerns
In summary, Vivo Bio Tech .’s fall to a 52-week low of Rs.29.21 is underpinned by a combination of subdued sales growth, declining profitability, constrained interest coverage, and underwhelming half-year financial results. The stock’s technical indicators remain weak, with prices trading below all major moving averages, while the broader market and sector indices have shown relative strength.
These factors collectively contribute to the stock’s current valuation and market positioning, reflecting a cautious market assessment of the company’s near-term prospects.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
